BioCentury
ARTICLE | Clinical News

CRL for Sandoz's biosimilar rituximab

May 4, 2018 4:24 PM UTC

The Sandoz unit of Novartis AG (NYSE:NVS; SIX:NOVN) said it received a complete response letter from FDA for a BLA for GP2013, the company's biosimilar of Rituxan/MabThera rituximab from Roche (SIX:ROG; OTCQX:RHHBY).

Sandoz said it is evaluating the letter...

BCIQ Company Profiles

Novartis AG

Roche

BCIQ Target Profiles

CD20